secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001640334-26-000461
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern
--------------------------------------------------------------------------------

- 1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.
- FY2025 net loss of $12.9M, up from $9.8M in FY2024; accumulated deficit reaches $63M.
- Cash and cash equivalents of $0.6M at Dec 2025; auditor includes going concern qualification.
- Loss on debt extinguishment totaled $1.158M ($825k + $333k related party) in FY2025.
- Convertible notes issued at 12% interest; total convertible debt of $609k at Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000461/0001640334-26-000461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000461/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer